Evidence map›Paper›PMID 22190392›Full record

ArticleClinical and vaccine immunology : CVI2012

Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice.

Mariana Baz, Mukesh Samant, Hakima Zekki, Pascale Tribout-Jover, Martin Plante, Anne-Marie Lanteigne, Marie-Eve Hamelin, Corey Mallett, Barbara Papadopoulou, Guy Boivin

Abstract readComparative Study
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Oral Immunization withBiomolecules · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mariana BazResearch Center in Infectious Diseases of the CHUL, CHUQ and Department of Microbiology and Immunology of Laval University, Quebec, Canada.
Mukesh Samant
Hakima Zekki
Pascale Tribout-Jover
Martin Plante
Anne-Marie Lanteigne
Marie-Eve Hamelin
Corey Mallett
Barbara Papadopoulou
Guy Boivin

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

Influenza A/H3N2 viruses have caused the most severe epidemics since 1968 despite current immunization programs with inactivated vaccines. We undertook a side-by-side preclinical evaluation of different adjuvants (Alum, AS03, and Protollin) and routes of administration (intramuscular [i.m.] and intranasal [i.n.]) for assessing their effect on the immunogenicity and cross-reactivity of inactivated split vaccines (A/H3N2/New York/55/2004). Humoral and T cell-mediated immune responses against the homologous virus and a heterologous drifted strain (A/H3N2/Wisconsin/67/2005) were measured in BALB/c mice at 2, 6, and 19 weeks postboost. The AS03- and Alum-adjuvanted i.m. vaccines induced at least an 8-fold increase over the nonadjuvanted vaccine in functional antibody titers against both the homotypic and heterotypic strains and low IgG2a and high IgG1 levels, suggesting a mixed Th1/Th2 response with a Th2 trend. The Protollin-adjuvanted i.n. vaccine induced the lowest IgG1/IgG2a ratio, which is indicative of a mixed Th1/Th2-type profile with a Th1 trend. This adjuvanted vaccine was the only vaccine to stimulate a mucosal IgA response. Whatever the timing after the boost, both hemagglutination inhibition (HAI) and microneutralization (MN) titers were higher with the AS03-adjuvanted i.m. vaccine than with the protollin-adjuvanted i.n. vaccine. Finally, the Alum-adjuvanted i.m. vaccine and the lower-dose Protollin-adjuvanted i.n. vaccine elicited significantly higher CD4(+) Th1 and Th2 responses and more gamma interferon (IFN-γ)-producing CD8(+) T cells than the nonadjuvanted vaccine. Our data indicate that the adjuvanted vaccines tested in this study can elicit stronger, more persistent, and broader immune responses against A/H3N2 strains than nonadjuvanted inactivated influenza vaccines.

Indexed as

Adjuvants, ImmunologicAdministration, IntranasalAlum CompoundsAnimalsAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCysteine EndopeptidasesDrug CombinationsDrug Evaluation, PreclinicalHemagglutination Inhibition TestsImmunity, CellularImmunity, HumoralImmunoglobulin AImmunoglobulin GInfluenza A Virus, H3N2 SubtypeAdjuvants, ImmunologicAlum Compoundsaluminum sulfateAntibodies, ViralCysteine EndopeptidasesDrug CombinationsImmunoglobulin AImmunoglobulin GInfluenza VaccinesInterferon-gammaLipopolysaccharidesProtollin

Identifiers

PMID22190392
PMCPMC3272927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.